Post USFDA nod, Bluebird Bio USD 2.8 million gene therapy becomes most expensive drug Ruchika Sharma19 Aug 2022 11:02 AM GMTBluebird has pitched Zynteglo as a potential one-time treatment that could do away with the need for transfusions, resulting in savings for patients...
USFDA panel backs Bluebird bio gene therapy for blood disorder Ruchika Sharma12 Jun 2022 6:30 AM GMTThe FDA is expected to decide on beti-cel's fate by Aug. 19 and eli-cel's by Sept. 16. The agency is not required to follow its advisers'...
Bristol-Myers Squibb gets USFDA nod to multiple myeloma therapy Ruchika Sharma29 March 2021 4:45 AM GMTNew Delhi: The U.S. Food and Drug Administration has approved Bristol-Myers Squibb Co and bluebird bio Inc's multiple myeloma therapy, ide-cel,...
Bristol Myers Squibb gets EMA validation for Idecabtagene Vicleucel, CC-486 Ruchika Sharma25 May 2020 10:23 AM GMTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Applications (MAA)...
